Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14791000 | 0.87 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791127 | 0.85 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14790994 | 0.85 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791020 | 0.83 | JAK2 (0.36) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL12066232 | 0.83 | JAK2 (0.37) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791055 | 0.82 | CD274 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791090 | 0.81 | CD274 (0.39) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791047 | 0.81 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL12067992 | 0.80 | CD274 (0.37) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL14791091 | 0.80 | CD274 (0.38) | JAK2JAK1TYK2JAK3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.